External validation of a risk model of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma
| Autor: | Matthias Schwenkglenks, Ruth Pettengell, Zsolt Szabo, Alena M. Pfeil, Kate Bendall |
|---|---|
| Přispěvatelé: | University of Zurich, Schwenkglenks, Matthias |
| Rok vydání: | 2013 |
| Předmět: |
Oncology
Male Risk Cancer Research medicine.medical_specialty Databases Factual medicine.medical_treatment 2720 Hematology 610 Medicine & health White blood cell Internal medicine Antineoplastic Combined Chemotherapy Protocols Medicine Humans 1306 Cancer Research Prospective Studies Intensive care medicine Serum Albumin Aged Febrile Neutropenia Aged 80 and over Chemotherapy Models Statistical Receiver operating characteristic business.industry Lymphoma Non-Hodgkin External validation Reproducibility of Results Hematology 10060 Epidemiology Biostatistics and Prevention Institute (EBPI) Middle Aged medicine.disease Lymphoma medicine.anatomical_structure ROC Curve Observational study 2730 Oncology Female business Complication Febrile neutropenia |
| Zdroj: | Leukemialymphoma. 54(11) |
| ISSN: | 1029-2403 |
| Popis: | Febrile neutropenia (FN) is a common and serious complication of chemotherapy treatment. Clinical risk models may help to identify patients at high risk of FN but must undergo external validation before implementation in medical practice. Therefore, this study externally validated previously published clinical models of FN occurrence during chemotherapy in 240 patients with non-Hodgkin lymphoma by using an independent observational dataset (n = 1829). The models demonstrated predictive ability, and validation criteria for predicting any cycle of FN were partially met but a larger than expected decrease in performance was noted (area under the receiver operating characteristic curve was 0.71 in the validation dataset and 0.83 in the training dataset). Age, weight, baseline white blood cell count and planned chemotherapy parameters were confirmed to predict FN risk. Chemotherapy dose reductions, dose delays and colony-stimulating factor use were confirmed as risk modifiers during treatment. Further work is needed to improve the predictive ability of FN risk models. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |